-
J&J's Janssen Denied Data Protection Rights For Ketamine Analog Spravato In Canada, Court Rules 'Not An Innovative Drug'
Monday, August 9, 2021 - 2:19pm | 1161Read More...The Federal Court of Appeals in Canada ratified a Ministry of Health decision to refuse to provide Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson (NYSE: JNJ), data protection for Spravato, a ketamine analog approved for depression. Spravato is the first...
-
Cidara Therapeutics Stock Rises After Collaboration Agreement Janssen For Influenza Candidates
Monday, April 5, 2021 - 8:05am | 282Read More...Cidara Therapeutics Inc (NASDAQ: CDTX) has entered into an exclusive worldwide license and collaboration agreement with Janssen Pharmaceuticals Inc, a unit of Johnson & Johnson (NYSE: JNJ), to develop and commercialize Cidara's Cloudbreak antiviral...
-
SpringWorks Therapeutics Stock Is Trading Higher After Nirogacestat Combo Study Starts Dosing In Multiple Myeloma Patients
Thursday, April 1, 2021 - 9:17am | 326Read More...SpringWorks Therapeutics Inc (NASDAQ: SWTX) has dosed the first patient in a Phase 1b clinical trial evaluating nirogacestat combined with Johnson & Johnson's (NYSE: JNJ)Janssen's teclistamab in patients with relapsed or refractory multiple myeloma....
-
AC Immune's Alzheimer's Vaccine Candidate Elicit Response In Early-Stage Study; Shares Rally
Thursday, February 11, 2021 - 9:16am | 289Read More...AC Immune SA (NASDAQ: ACIU) soars in premarket on robust volume, on the heels of positive interim results from its ongoing Phase 1b/2a trial evaluating its anti-phospho-Tau (pTau) vaccine candidate ACI-35.030 for the treatment of Alzheimer's disease. ACI-35.030 is under...
-
GlaxoSmithKline's ViiV Healthcare Bags EU Marketing Authorization For Long-Acting HIV Treatment
Monday, December 21, 2020 - 7:26am | 450Read More...British pharmaceutical company GlaxoSmithKline PLC’s (NYSE: GSK) majority-owned subsidiary ViiV Healthcare received the marketing authorization approval for its HIV treatment in the European Union, the company announced on Monday. What Happened: ViiV announced that...
-
Analysts React To Arrowhead's Janssen Collaboration: Downside In Stock May Be 'Misguided'
Thursday, October 4, 2018 - 1:53pm | 492Read More...Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) stock tanked 15 percent Thursday after the company announced a new $3.7-billion deal to license its ARO-HBV treatment for chronic hepatitis B to Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Pharmaceuticals. Investors clearly weren’t...
-
Arrowhead Announces $3.7B License Agreement With Janssen For Gene-Silencing Drug
Thursday, October 4, 2018 - 10:12am | 382Read More...Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) develops medicines to treat intractable diseases. The company’s therapies trigger the RNA interference to alter target genes, as a natural process of gene silencing. What Happened Arrowhead announced entrance into a $3.7-billion license and...
-
Exclusive: Following Up Akebia, Johnson & Johnson's Research And License Agreement
Friday, February 17, 2017 - 11:21am | 909Read More...On Monday, Akebia Therapeutics Inc (NASDAQ: AKBA) signed a $1 million research and license agreement with Johnson & Johnson (NYSE: JNJ) to access hundreds of hypoxia inducible factor (HIF)-targeted compounds. This access includes a coveted preclinical candidate for inflammatory bowel disease (...
-
Ladenburg On Biotech: Starts Achillion, Alnylam, Corcept, Trevana At Buy
Thursday, February 2, 2017 - 10:21am | 701Read More...Ladenburg Thalmann’s Christopher S. James initiated coverage of four biotech companies with a Buy rating, given that each has a promising lead drug candidate that is expected to drive growth in the near future. Achillion Pharmaceuticals James initiated coverage of Achillion Pharmaceuticals,...
-
Depomed Surges 8% Following NUCYNTA Acquisition From Janssen Pharmaceuticals
Friday, January 16, 2015 - 9:58am | 178Read More...Investors cheered the Depomed Inc (NASDAQ: DEPO) decision to acquire the U.S. rights to the NUCYNTA franchise as the stock traded 8 percent higher in Friday's premarket. The company will acquire the franchise rights from Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Pharmaceuticals,...
-
Depomed To Acquire Rights To NUCYNTA Franchise For $1.05 Billion
Thursday, January 15, 2015 - 6:23pm | 193Read More...Depomed Inc (NASDAQ: DEPO) announced Thursday that it will acquire the U.S. rights to the NUCYNTA franchise from Johnson & Johnson (NYSE: JNJ) subsidiary Janssen Pharmaceuticals, Inc. for $1.05 billion. According to the company’s press release, “The NUCYNTA franchise...
